Evidence map›Paper›PMID 36874001›Full record

ArticleFrontiers in pharmacology2023

Hyunki Cho, Young Jun Kim, Jung-Woo Chae, Markus R Meyer, Sang Kyum Kim, Chang Seon Ryu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Hyunki ChoEnvironmental Safety Group, KIST Europe Forschungsgesellschaft mbH, Saarbrücken, Germany.
Young Jun KimEnvironmental Safety Group, KIST Europe Forschungsgesellschaft mbH, Saarbrücken, Germany.
Jung-Woo ChaeCollege of Pharmacy, Chungnam National Univerisity, Daejeon, Republic of Korea.
Markus R MeyerDepartment of Experimental and Clinical Toxicology, Center for Molecular Signaling (PZMS), Institute of Experimental and Clinical Pharmacology and Toxicology, Saarland University, Homburg, Germany.
Sang Kyum KimCollege of Pharmacy, Chungnam National Univerisity, Daejeon, Republic of Korea.
Chang Seon RyuEnvironmental Safety Group, KIST Europe Forschungsgesellschaft mbH, Saarbrücken, Germany.
Chungnam National University · KRKIST Europe · DESaarland University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SARS-CoV-2 pandemic requires a new therapeutic target for viral infection, and papain-like protease (Plpro) has been suggested as a druggable target. This

Indexed as

cytochrome P450GRL0617hepatic metabolismhuman liver microsomeLC-QTOF

Identifiers

PMID36874001
PMCPMC9975351
OpenAlexW4320920452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.